</s><s><s><s> human papillomavirus ( hpv ) is the most common sexually transmitted disease in the united states. 
 the incidence of hpv infection is increasing worldwide, particularly in the developing world, and the incidence is expected to increase further in the coming years, especially in the european union and the north america. in this review, 
 we summarize the most recent advances in hpv vaccine development, immunogenicity and reactogenicity, and clinical efficacy of a prophylactic and monovalent vaccine against hpv infections and disease in men and women, as well as the long - term efficacy of an alternative schedule of vaccine administration in women with virological evidence of infection. </s>